NASDAQ:GERN Geron - GERN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.34 -0.03 (-0.89%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.32▼$3.4150-Day Range$2.04▼$3.4052-Week Range$0.99▼$3.84Volume3.64 million shsAverage Volume17.15 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Geron MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside64.7% Upside$5.50 Price TargetShort InterestHealthy5.96% of Shares Sold ShortDividend StrengthN/ASustainability-2.15Upright™ Environmental ScoreNews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector445th out of 1,054 stocksPharmaceutical Preparations Industry219th out of 517 stocks 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Geron has a forecasted upside of 64.7% from its current price of $3.34.Amount of Analyst CoverageGeron has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.96% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Geron has recently decreased by 22.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 2.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a 6.71% net impact score from Upright. Geron seems to create the most significant positive value in categories "Jobs", "Taxes", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.15. Previous Next 3.0 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Geron this week, compared to 3 articles on an average week.Search Interest36 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows33 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 725% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Geron is held by insiders.Percentage Held by Institutions49.75% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.38) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 8.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Geron (NASDAQ:GERN) StockGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesJanuary 27, 2023 | finance.yahoo.comGeron (GERN) Stock Sinks As Market Gains: What You Should KnowJanuary 27, 2023 | americanbankingnews.comGeron (NASDAQ:GERN) Upgraded by StockNews.com to "Sell"January 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 12, 2023 | finance.yahoo.comGeron to Present at the B. Riley Securities 3rd Annual Virtual Oncology ConferenceJanuary 11, 2023 | finance.yahoo.comAre Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?January 11, 2023 | finance.yahoo.comGeron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.January 10, 2023 | finance.yahoo.comGeron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 MillionJanuary 6, 2023 | finance.yahoo.comGeron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded WarrantsJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 5, 2023 | finance.yahoo.comGeron (GERN) Up on Imetelstat Data on Myelodysplastic SyndromesJanuary 4, 2023 | finance.yahoo.comLongtime Bay Area biotech follows up late-stage trial data with planned $175M stock saleJanuary 4, 2023 | finance.yahoo.comGeron Corporation Announces Proposed Public Offering of Common StockJanuary 4, 2023 | investorplace.comWhy Is Geron (GERN) Stock Soaring 50% Today?January 4, 2023 | finance.yahoo.comGeron Stock Surges After Encouraging Data From Rare Blood Cancer TrialJanuary 4, 2023 | finance.yahoo.comThese 2 Nasdaq Biotechs Are Making Big Moves WednesdayJanuary 4, 2023 | finance.yahoo.comGeron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDSJanuary 4, 2023 | finance.yahoo.comGeron Corp's blood cancer drug succeeds in late-stage studyJanuary 3, 2023 | finance.yahoo.comGeron Announces Conference Call for Top-Line Results from IMerge Phase 3December 19, 2022 | finance.yahoo.comWhile institutions own 43% of Geron Corporation (NASDAQ:GERN), individual investors are its largest shareholders with 49% ownershipDecember 12, 2022 | finance.yahoo.comGeron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS PatientsDecember 7, 2022 | finance.yahoo.comWhy Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?December 4, 2022 | finance.yahoo.comTipRanks ‘Perfect 10’ List: 2 Stocks Under $5 That Are Worth Looking IntoDecember 1, 2022 | seekingalpha.comGeron: Expect Topline MDS Data In Early JanuaryNovember 8, 2022 | finance.yahoo.comGeron to Participate in Stifel 2022 Healthcare ConferenceNovember 4, 2022 | finance.yahoo.comGeron (GERN) Q3 2022 Earnings Call TranscriptOctober 27, 2022 | finance.yahoo.comGeron to Announce Third Quarter 2022 Financial Results on November 3, 2022October 25, 2022 | finance.yahoo.comInvesting in Geron (NASDAQ:GERN) a year ago would have delivered you a 55% gainSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Company Calendar Last Earnings11/03/2022Today1/29/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+64.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,110,000.00 Net Margins-8,563.80% Pretax Margin-8,563.80% Return on Equity-110.76% Return on Assets-58.66% Debt Debt-to-Equity Ratio0.35 Current Ratio2.68 Quick Ratio2.68 Sales & Book Value Annual Sales$1.39 million Price / Sales916.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book8.56Miscellaneous Outstanding Shares381,230,000Free Float358,361,000Market Cap$1.27 billion OptionableOptionable Beta0.76 Key ExecutivesDr. John A. Scarlett M.D. (Age 72)Chairman, Pres & CEO Comp: $1.26MMs. Olivia Kyusuk Bloom (Age 54)Exec. VP of Fin., CFO & Treasurer Comp: $743.27kDr. Andrew J. Grethlein (Age 59)Exec. VP & COO Comp: $767.28kMs. Melissa A. Kelly Behrs (Age 59)Exec. VP of Bus. Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 53)Exec. VP of Corp. Strategy & Chief Commercial Officer Comp: $654.89kMs. Aron FeingoldVP of Investor Relations & Corp. CommunicationsMr. Stephen N. Rosenfield J.D. (Age 73)Exec. VP, Chief Legal Officer & Corp. Sec. Ms. Shannon OdamVP of HRMr. Edward E. Koval (Age 61)Exec. VP & Chief Bus. Officer Dr. Faye Feller M.D. (Age 41)Exec. VP & Chief Medical Officer More ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXImmunoGenNASDAQ:IMGNOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 16,956 shares on 1/23/2023Ownership: 0.014%Private Advisor Group LLCBought 20,000 shares on 1/18/2023Ownership: 0.014%Douglas Lane & Associates LLCBought 83,900 shares on 1/17/2023Ownership: 0.022%Tennessee Valley Asset Management PartnersBought 10,350 shares on 1/12/2023Ownership: 0.003%Bank of New York Mellon CorpBought 68,331 shares on 12/8/2022Ownership: 0.323%View All Institutional Transactions GERN Stock - Frequently Asked Questions Should I buy or sell Geron stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price forecast for 2023? 4 brokers have issued 1-year target prices for Geron's shares. Their GERN share price forecasts range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 64.7% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2023? Geron's stock was trading at $2.42 on January 1st, 2023. Since then, GERN shares have increased by 38.0% and is now trading at $3.34. View the best growth stocks for 2023 here. Are investors shorting Geron? Geron saw a drop in short interest in January. As of January 15th, there was short interest totaling 22,710,000 shares, a drop of 22.2% from the December 31st total of 29,190,000 shares. Based on an average daily trading volume, of 8,130,000 shares, the days-to-cover ratio is presently 2.8 days. View Geron's Short Interest. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company earned $0.30 million during the quarter, compared to the consensus estimate of $0.12 million. Geron had a negative trailing twelve-month return on equity of 110.76% and a negative net margin of 8,563.80%. What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). What is Geron's stock symbol? Geron trades on the NASDAQ under the ticker symbol "GERN." Who are Geron's major shareholders? Geron's stock is owned by many different retail and institutional investors. Top institutional investors include Douglas Lane & Associates LLC (0.02%), Allspring Global Investments Holdings LLC (0.01%), Private Advisor Group LLC (0.01%) and Tennessee Valley Asset Management Partners (0.00%). View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Geron's stock price today? One share of GERN stock can currently be purchased for approximately $3.34. How much money does Geron make? Geron (NASDAQ:GERN) has a market capitalization of $1.27 billion and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How can I contact Geron? Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750. This page (NASDAQ:GERN) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.